Compass Pathways to Showcase Psychedelic Therapy Progress at Cantor Conference — Compass Pathfinder Limited

Event summary

Compass Pathways will participate in the 2026 Cantor Global Healthcare Conference on September 9, 2026.
The company will host a fireside chat at 3:20pm ET and a panel on psychedelics at 4:30pm ET.
COMP360 psilocybin has Breakthrough Therapy designation from the FDA and ILAP designation in the UK for treatment-resistant depression (TRD).
Compass is conducting the world’s largest classic psychedelic clinical program in TRD and a late-stage trial for PTSD.

The big picture

Compass Pathways is positioning itself as a leader in psychedelic-assisted therapy, leveraging regulatory designations to accelerate development. The Cantor Conference appearance underscores the company’s push to engage investors and stakeholders as it navigates the competitive landscape of mental health innovation. With a focus on treatment-resistant depression and PTSD, Compass is betting on the scalability of its proprietary psilocybin treatment model.

What we're watching

Regulatory Progress: Whether COMP360 psilocybin can maintain its Breakthrough Therapy and ILAP designations through late-stage trials.
Market Positioning: How Compass Pathways differentiates itself in the growing psychedelic therapy space.
Clinical Execution: The pace at which Compass can advance its PTSD trial alongside its TRD program.